34074-28-7Relevant articles and documents
The syntheses of 4,4'-(1,n-dioxaalkane)-bisbenzaldehydes and 4,4'-(1,n- dioxaalkane)-bis(α-methoxy phenylacetic acids)
Jiang, Jianjun,Compere Jr., Edward L.
, p. 1041 - 1050 (1998)
The syntheses of 4,4'-(1,n-dioxaalkane)-bis(α-methoxyphenylacetic acids) were conducted using a base-catalyzed reaction. The reactants were potassium hydroxide (or lithium hydroxide/lithium chloride), bromoform, methanol and 4,4'-(1,n-dioxaalkane)-bisbenz
Synthesis, Molecular Docking Studies, and Anticonvulsant Evaluation of Novel bis-Phenylhydrazones against Chemically induced Seizures in Mice
Siddiqi, Humaira Masood,Tabasum, Aneela,Qasim, Sumera,Akhtar, Muhammad Shoaib,Kalsoom, Saima,Ansari, Farzana Latif
, p. 940 - 952 (2017)
A series of novel bis-phenylhydrazones were synthesized by the condensation of dialdehydes with phenylhydrazine to evaluate them for their anticonvulsant activity. Efficacy of newly synthesized compounds against pentylenetetrazole (PTZ)-induced, strychnin
Synthesis, characterization and anticancer activity of dinuclear ruthenium(II) complexes linked by an alkyl chain
Zhang, Yan,Lai, Lu,Cai, Ping,Cheng, Gong-Zhen,Xu, Xi-Ming,Liu, Yi
, p. 5805 - 5812 (2015)
A series of 1,10-phenanthroline-based dinucleating bridging ligands BL1-3 and their dinuclear ruthenium Ru(ii) complexes [(bpy)2Ru(BL1-3)Ru(bpy)2](PF6)4 (bpy = 2,2′-bipyridine; PF6/su
Synthesis, antitumor activity, enzyme assay, DNA binding and molecular docking of Bis-Schiff bases of pyrazoles
Morsy, Nesrin M.,Hassan, Ashraf S.,Hafez, Taghrid S.,Mahran, Mohamed R. H.,Sadawe, Inass A.,Gbaj, Abdul M.
, p. 47 - 59 (2020/07/27)
A novel series of Bis-Schiff bases of pyrazoles 9–24 were synthesized by the direct condensation of 5-aminopyrazoles 4a–d with dialdehydes 8a–d in ethanol. The newly synthesized Bis-Schiff bases of pyrazoles 9–24 were characterized and confirmed by analyt
BIVALENT LECA INHIBITORS TARGETING BIOFILM FORMATION OF PSEUDOMONAS AERUGINOSA
-
Page/Page column 31-32; 42, (2021/05/15)
The present invention relates to divalent compounds binding to LecA. The compounds are useful to block biofilm formation of Pseudomonas aeruginosa. The invention further relates to pharmaceutical compositions comprising these compounds and to therapeutic methods and uses of these compounds, in particular to therapeutic methods and uses for the treatment of Pseudomonas aeruginosa infections in a subject. The invention also relates to imaging of infections, such as biofilms produced by Pseudomonas aeruginosa, by using these divalent compounds.